Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

COVID-19 and COVID-19 Vaccine in Japan—A Review from a General Physician's Perspective

Version 1 : Received: 24 May 2023 / Approved: 26 May 2023 / Online: 26 May 2023 (04:05:24 CEST)

A peer-reviewed article of this Preprint also exists.

Kusunoki, H. COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective. Pharmacoepidemiology 2023, 2, 188-208. Kusunoki, H. COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective. Pharmacoepidemiology 2023, 2, 188-208.

Abstract

More than 3 years have passed since the emergence of COVID-19. On May 8, 2023, COVID-19 in Japan was downgraded to Category 5 by the Infectious Disease Control Law. In Japan, at the beginning of the COVID-19 pandemic in 2020, cases of infection and deaths from severe disease were few compared with those of Western countries. However, in the medical field, screening for COVID-19 was given top priority, resulting in confusion and proving disadvantageous for many patients, also the overreaction to COVID-19 as the most important issue in society can be attributed largely to statements by infectious disease experts. In addition, the mRNA vaccine emerged in 2021, and most of the population was vaccinated up to two times within a short period of less than 1 year because infectious disease experts strongly promoted vaccination. After 2022, when vaccination progressed, and the Omicron strain, which is an attenuated strain, became the mainstay of the SARS-CoV-2, the number of severe cases of COVID-19 decreased significantly; however, the number of infected people increased dramatically instead. A significant portion of the population is thought to have hybrid immunity due to vaccination plus natural infection and maintains high antibody titers. Henceforth, additional vaccination should be given preferentially to those who will benefit most from it. Conversely, measures against COVID-19 caused serious damage to the economy and society. Policies that not only address countermeasures against infection, but also those that encompass the economy and society as a whole are necessary.

Keywords

COVID-19; SARS-CoV-2; vaccines; breakthrough infection; hybrid immunity; SARS-CoV-2 antibody

Subject

Medicine and Pharmacology, Internal Medicine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.